[Remdesivir (COVID-19, requirement for additional oxygen supply, = 4 weeks - < 12 years of age) - Benefit assessment according to § 35a Social Code Book V]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004341
German
Original Title:
Remdesivir (COVID-19, mit zusaetzlicher Sauerstoffzufuhr, ≥ 4 Wochen bis < 12 Jahre)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a22-113.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a22-113_remdesivir_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- COVID-19
- COVID-19 Drug Treatment
- Antiviral Agents
- Child
- Child, Preschool
- Infant
- SARS-CoV-2
- Coronavirus Infections
Keywords
- Remdesivir
- COVID-19
- Child - Preschool
- Infant
- Child
- Benefit Assessment
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.